Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 6Carcinoma, Hepatocellular 4Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoma, Kaposi 1Pancreatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1HIV Infections 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Medullary 1Carcinoma, Adenosquamous 1Adenocarcinoma 1

Interventions

pembrolizumab 1fluoroazomycin arabinoside 1cabozantinib 1Metformin 1Hysterectomy 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Adenosquamous × cabozantinib × Gynecologic × Clear all
NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

University of South Alabama

Phase 2 Terminated
5 enrolled
Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡